Skip to main content

Search

Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
erventional prospective study for the effectiveness, tolerability and adherence of Asciminib after two previous TKIs in Patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP) in Saudi Arabia. (ASC4REAL) Novartis Ongoing Scemblix (Asciminib/ ABL001) 4 CABL001ASA King Abdulaziz Medical City NG (Riyadh)
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER™-ON) Boehringer Ingelheim Ongoing BI 1015550 3 1305-0031 King Abdulaziz Medical City NG (Riyadh)
Netupitant and palonosetron fixed-dose combination versus 5-HT3 receptor antagonists in preventing chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: A randomized, open-label, phase IV trial PI initiatied Ongoing Netupitant and palonosetron, Granisetron transdermal patch, Ondansetron 4 24-1205 King Abdullah Medical City (Makkah)
A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT) Astrazeneca Ongoing Ultomiris (Ravulizumab) 4 ALX-NMO-50 King Khalid University Hospital (Riyadh),King Abdulaziz Medical City NG (Jeddah)
A PHASE III, PROSPECTIVE OPEN-LABEL, MULTI-CENTER SINGLE ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) PROFILE OF INTRAVENOUS HUMAN NORMAL IMMUNOGLOBULIN (IgG) IN PRIMARY IMMUNODEFICIENCY DISEASE (PID) PATIENTS Celgene Corporation Ongoing Golcadomide,BMS-986369 / CC-99282 3 SKP-LIV_PID_III_2023 King Abdulaziz University Hospital (Jeddah), King Fahad Hospital (Jeddah) ,Al-Aziziyah Maternity and Children's Hospital
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) Celgene Corporation Ongoing Golcadomide,BMS-986369 / CC-99282 3 CA0731020 King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam), King Abdullah Medical Complex (Jeddah)
INTERnational STudy Evaluating Lupus Outcomes after Anifrolumab Real-World Use (INTERSTELLAR): Multi-National, Observational, Prospective, Post-Launch, Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice King Faisal Specialist Hospital and Research Center (Riyadh) Ongoing Semaglutide 3 2241130 King Faisal Specialist Hospital and Research Center (Riyadh)
Survey assessing prospective patient’s short-term treatment satisfaction and Quality of Life in patients with Hidradenitis Suppurativa initiated on Cosentyx (Secukinumab) in routine clinical practice in Saudi Arabia Novartis Ongoing Secukinumab 4 CAIN457MSA King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Jeddah)
A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod IV in Adult Participants With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis Argenx BV Ongoing Efgartigimod IV 3 ARGX-113-2308 King Faisal Specialist Hospital and Research Center (Riyadh),King Abdulaziz Medical City NG (Riyadh)
Effect and safety of Semaglutide in diabetic kidney transplant recipients with obesity AbbVie Ongoing Risankizumab 3 M23-784 Aseer Central Hospital (Abha), International Medical Center (Jeddah), King Khalid University Hospital (Riyadh)
View 1 - 10 From 756